RxDoctor Payments Data

Paige Leykam, APRN

Nurse Practitioner · Surprise, AZNPI 1033470968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 985 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,708in general payments, 2019–2025

Across 985 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Johnson & Johnson$1K
  • AbbVie$1K
  • Novartis$1K
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$20,74391%
  • Education$1,9659%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen71$1,940
AstraZeneca(2 entities)60$1,701
E.r. Squibb & Sons, L.L.C.82$1,386
Johnson & Johnson(2 entities)59$1,321
AbbVie66$1,158
Novartis58$1,119
Pfizer60$1,112
Merck37$842
GSK37$703
Sanofi28$691
Seagen Inc.18$673
Lilly USA, LLC30$592
Incyte Corporation25$576
Daiichi Sankyo Inc.23$569
Astellas Pharma US Inc12$547
Sobi, Inc23$545
Bristol Myers Squibb29$537
AVEO Pharmaceuticals, Inc.11$347
UCB, Inc.11$343
Takeda Pharmaceuticals U.S.A., Inc.10$311
Genmab U.S., Inc.7$280
EMD Serono, Inc.13$270
Pharmacyclics LLC, An Abbvie Company12$268
Rigel Pharmaceuticals, Inc.10$263
Genentech USA, Inc.10$252
Jazz Pharmaceuticals Inc.9$242
Bayer10$236
Sumitomo Pharma America, Inc.2$201
Eisai Inc.9$197
Sanofi-aventis U.S. LLC2$185
Gilead(2 entities)8$177
Exelixis Inc.7$169
Array Biopharma Inc9$166
Ipsen Biopharmaceuticals, Inc8$165
Regeneron Healthcare Solutions, Inc.5$145
Pharmacosmos Therapeutics Inc.7$143
Servier Pharmaceuticals LLC6$131
Sun Pharmaceutical Industries Inc.5$119
Blueprint Medicines Corporation5$111
Radius Health, Inc.5$108
Stemline Therapeutics Inc.4$100
G1 Therapeutics, Inc.4$97
Beigene USA, Inc.4$81
Springworks Therapeutics, Inc.3$77
Menarini Silicon Biosystems, Inc.2$73
Adaptive Biotechnologies Corporation4$73
Kyowa Kirin, Inc.3$73
Boehringer Ingelheim3$72
Mirati Therapeutics, Inc.4$70
Pharmaessentia USA Corporation4$66
Octapharma USA, Inc.2$65
Karyopharm Therapeutics Inc.4$63
Tersera Therapeutics LLC2$63
Beone Medicines USA, Inc.2$61
Legend Biotech USA Inc.3$58
Tempus AI, Inc3$58
Organon4$45
Abbott1$44
Amneal Pharmaceuticals LLC2$44
Teva Pharmaceuticals USA, Inc.3$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,708 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$90,376
Medicare patients
96
Services billed
7,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$144,322
VenclextaVenetoclax11$130,619
XareltoRivaroxaban40$39,248
Dabigatran EtexilateDabigatran Etexilate Mesylate29$5,224
Hydroxyurea59$1,774
Ondansetron OdtOndansetron69$985
Prochlorperazine Maleate50$555
Bicalutamide33$473
Anastrozole34$424
Penicillin V Potassium14$377
Dexamethasone32$321
Gabapentin12$210
Oxycodone Hcl16$142
Prednisone19$100
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,112$144,322179 claims
AbbVieVenclexta$1,158$130,61911 claims
Johnson & JohnsonXarelto$1,321$39,24840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →